<DOC>
	<DOCNO>NCT01757535</DOCNO>
	<brief_summary>This study enroll approximately 460 subject , age 55 old , diagnosis de novo AML ( Acute Myeloid Leukemia ) AML secondary prior myelodysplastic disease chronic myelomonocytic leukemia ( CMML ) , achieve first Complete remission ( CR ) / Complete remission incomplete blood count recovery ( CRi ) follow induction without consolidation chemotherapy . Subjects previously achieve CR/CRi hypomethylating agent exclude study .</brief_summary>
	<brief_title>Efficacy Oral Azacitidine Plus Best Supportive Care Maintenance Therapy Subjects With Acute Myeloid Leukemia Complete Remission</brief_title>
	<detailed_description>This international , multicenter , placebo-controlled , phase3 study double-blind , randomize , parallel-group design de novo AML ( Acute Myeloid Leukemia ) AML secondary prior diagnosis Myelodysplasic Syndromes ( MDS ) chronic myelomonocytic leukemia ( CMML )</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Male female subject â‰¥ 55 year age 2 . Newly diagnose , histologically confirm de novo AML AML secondary prior myelodysplastic disease CMML ( Chronic myelomonocytic leukemia ) 3 . First Complete remission ( CR ) / Complete remission incomplete blood count recovery ( CRi ) induction therapy + consolidation therapy within 4 month ( +/ 7 day achieve CR CRi ) 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 , 3 1 . AML inv ( 16 ) , ( 8 ; 21 ) , ( 16 ; 16 ) , ( 15 ; 17 ) , ( 9 ; 22 ) molecular evidence translocation 2 . Prior bone marrow stem cell transplantation 3 . Have achieve CR/CRi follow therapy hypomethylating agent 4 . Diagnosis malignant disease within previous 12 month 5 . Proven Central Nervous System ( CNS ) leukemia</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Maintenance therapy</keyword>
	<keyword>AML</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>oral Azacitidine</keyword>
	<keyword>best supportive care</keyword>
	<keyword>complete remission</keyword>
</DOC>